Minorities in the US bear a disproportionate burden of cancer compared with other population groups. The health disparities and measurable differences in outcomes manifest across the cancer care continuum, from prevention and diagnosis, through treatment, monitoring and mortality. This understanding guided ConcertAI to form ERACE (Engaging Research to Achieve Cancer Care Equity) which is a multidisciplinary initiative to better understand cancer disparities and create innovative solutions to eliminate them.

Black American women are 2x as likely to be diagnosed with triple negative breast cancer (TNBC) compared to white women. Black American men are 37% more likely to develop lung cancer than white men. Hispanic men are 10% less likely to be diagnosed with prostate cancer than non-Hispanic white men. American Indian/Alaska Native men are 40% more likely to have stomach cancer than white men, and 2x as likely to die from it. Liver cancer death rate is 60% higher in Asian Americans compared to whites.

A new study by ConcertAI based on patient-reported outcomes makes another compelling case for addressing disparities in treatment outcomes and racially biased access to clinical trials – and for why a new research focus is imperative to improve (and save) the lives of racial minorities diagnosed with cancer.